Effect of Macitentan on Hospitalizations-Reference-Cited by-同舟云学术

Effect of Macitentan on Hospitalizations

Published:2015-01 Issue:1 Volume:3 Page:1-8
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Channick Richard N.,Delcroix Marion,Ghofrani Hossein-Ardeschir,Hunsche Elke,Jansa Pavel,Le Brun Franck-Olivier,Mehta Sanjay,Pulido Tomás,Rubin Lewis J.,Sastry B.K.S.,Simonneau Gérald,Sitbon Olivier,Souza Rogério,Torbicki Adam,Galiè Nazzareno

Funder

Actelion Pharmaceuticals

Bayer HealthCare

Actelion Pharmaceuticals Ltd

GlaxoSmithKline

Pfizer

Gilead

Ikaria

Eli Lilly & Co.

United Therapeutics

Eli Lilly & Company

Bayer

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference26 articles.

1. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

2. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era;Humbert;Circulation,2010

3. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era;Condliffe;Am J Respir Crit Care Med,2009

4. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry;Benza;Chest,2012

5. Clinical worsening in trials of pulmonary arterial hypertension: results and implications;Galiè;Curr Opin Pulm Med,2010

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Features of treatment, hospitalization and working ability of newly diagnosed patients with pulmonary arterial hypertension before and after diagnosis verification;"Arterial’naya Gipertenziya" ("Arterial Hypertension");2024-04-30

2. Basic aspects of pathophysiology, diagnosis and treatment of patients with pulmonary arterial hypertension associated with human immunodeficiency virus infection: what has been achieved and what remains to be achieved?;Systemic Hypertension;2024-03-25

3. Treatment of pulmonary arterial hypertension: recent progress and a look to the future;The Lancet Respiratory Medicine;2023-09

4. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran;Value in Health Regional Issues;2023-03

5. Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials;Pulmonary Pharmacology & Therapeutics;2022-10